NCT02230878 - A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Healthy

Interventions

DRUG

JNJ-42847922 5 mg

Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.

DRUG

JNJ-42847922 10 mg

Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.

DRUG

JNJ-42847922 20 mg

Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.

DRUG

JNJ-42847922 40 mg

Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .

DRUG

Placebo

Participants will receive matching placebo from Day 1 up to Day 10.

Trial Locations (1)

Berlin